Young Cw

582 total citations
29 papers, 482 citations indexed

About

Young Cw is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Young Cw has authored 29 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Oncology and 4 papers in Genetics. Recurrent topics in Young Cw's work include Biochemical and Molecular Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer therapeutics and mechanisms (5 papers). Young Cw is often cited by papers focused on Biochemical and Molecular Research (8 papers), Cancer Treatment and Pharmacology (6 papers) and Cancer therapeutics and mechanisms (5 papers). Young Cw collaborates with scholars based in United States. Young Cw's co-authors include Gerald Schochetman, Burchenal Jh, Casper Es, Raymond Raymond, Arlin Za, Edward Miller, B Clarkson, Gralla Rj, Jeremy A. Roberts and C Schuman and has published in prestigious journals such as PubMed and MiJo.

In The Last Decade

Young Cw

28 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Young Cw United States 14 212 191 56 54 51 29 482
T. L. Loo United States 10 206 1.0× 175 0.9× 23 0.4× 39 0.7× 30 0.6× 27 522
J. Maroun Canada 13 203 1.0× 274 1.4× 35 0.6× 29 0.5× 120 2.4× 30 605
Timothy S. Collins United States 9 252 1.2× 146 0.8× 37 0.7× 34 0.6× 31 0.6× 10 461
C. J. Kovacs United States 18 240 1.1× 194 1.0× 37 0.7× 22 0.4× 31 0.6× 55 722
N S Datta United States 8 346 1.6× 113 0.6× 68 1.2× 37 0.7× 54 1.1× 12 546
Catherine Müller France 14 392 1.8× 347 1.8× 63 1.1× 38 0.7× 37 0.7× 24 680
M Musset France 14 138 0.7× 332 1.7× 80 1.4× 78 1.4× 35 0.7× 46 629
E. Laurensse Netherlands 13 408 1.9× 249 1.3× 18 0.3× 25 0.5× 64 1.3× 21 609
Monique Bedin France 10 188 0.9× 77 0.4× 33 0.6× 33 0.6× 25 0.5× 28 377
Paul A. Morse United States 13 458 2.2× 136 0.7× 37 0.7× 17 0.3× 68 1.3× 24 756

Countries citing papers authored by Young Cw

Since Specialization
Citations

This map shows the geographic impact of Young Cw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young Cw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young Cw more than expected).

Fields of papers citing papers by Young Cw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young Cw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young Cw. The network helps show where Young Cw may publish in the future.

Co-authorship network of co-authors of Young Cw

This figure shows the co-authorship network connecting the top 25 collaborators of Young Cw. A scholar is included among the top collaborators of Young Cw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young Cw. Young Cw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cw, Young. (1987). Revision of the crane fly genus Dicranoptycha in North America.. 53(5). 215–274. 12 indexed citations
2.
Cw, Young & Raymond Raymond. (1986). Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.. PubMed. 70(1). 51–63. 21 indexed citations
3.
Leyland-Jones, B, et al.. (1985). Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU).. PubMed. 69(1). 55–9. 18 indexed citations
4.
Es, Casper, et al.. (1984). Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.. PubMed. 68(3). 539–41. 3 indexed citations
5.
Cw, Young, et al.. (1983). Phase I trial of homoharringtonine administered as a 5-day continuous infusion.. PubMed. 67(7-8). 693–6. 28 indexed citations
6.
Za, Arlin, et al.. (1982). Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia.. PubMed. 66(7). 1479–85. 21 indexed citations
7.
Cw, Young, et al.. (1981). Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.. PubMed. 64(10-11). 1157–8. 11 indexed citations
8.
Cw, Young. (1981). Science, humanism and the Phase I trial.. PubMed. 11(1). 3–4. 1 indexed citations
9.
Es, Casper, Gralla Rj, D. P. Kelsen, et al.. (1981). Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.. PubMed. 64(4-5). 705–7. 12 indexed citations
10.
Es, Casper, et al.. (1980). Platinum concentrations in bile and plasma following rapid and 6-hour infusions of cis-dichlorodiammineplatinum(II).. PubMed. 63(11-12). 2023–5. 16 indexed citations
11.
Es, Casper, et al.. (1980). Phase I study of 6-diazo-5-oxo-L-norleucine (DON).. PubMed. 64(12). 1247–51. 22 indexed citations
12.
Cw, Young, et al.. (1980). Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.. PubMed. 64(1). 53–5. 9 indexed citations
13.
Ih, Krakoff, et al.. (1979). Phase I evaluation of tetrahydrouridine combined with cytosine arabinoside.. PubMed. 63(8). 1245–9. 22 indexed citations
14.
Cw, Young, et al.. (1979). Phase II trial of pyrazofurin in patients with multiple myeloma refractory to standard cytotoxic therapy.. PubMed. 63(8). 1403–4. 7 indexed citations
15.
Cw, Young, et al.. (1978). THE EVOLUTION OF FERRITE CONTROL COMPONENTS. MiJo. 21. 33–37. 3 indexed citations
16.
Rj, Gralla, et al.. (1978). Phase II evaluation of pyrazofurin in patients with carcinoma of the lung.. PubMed. 62(3). 451–2. 8 indexed citations
17.
Cw, Young, et al.. (1967). Comparative aspects of the pharmacology of the antimetabolites.. PubMed. 26(4). 1139–45. 9 indexed citations
18.
Cw, Young, et al.. (1967). Inhibition of DNA synthesis by hydroxyurea: structure-activity relationships.. PubMed. 27(3). 535–40. 85 indexed citations
19.
Cw, Young, et al.. (1960). The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2'-deoxyuridine).. PubMed. 8. 77–83. 50 indexed citations
20.
Cw, Young, Ellison Rr, Robert A. Kaufman, et al.. (1960). The clinical evaluation of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in solid tumors in adults: a progress report.. PubMed. 6. 17–20. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T. L. Loo Breakdown of academic impact, for papers by J. Maroun Breakdown of academic impact, for papers by Timothy S. Collins Breakdown of academic impact, for papers by C. J. Kovacs Breakdown of academic impact, for papers by N S Datta Breakdown of academic impact, for papers by Catherine Müller Breakdown of academic impact, for papers by M Musset Breakdown of academic impact, for papers by E. Laurensse Breakdown of academic impact, for papers by Monique Bedin Breakdown of academic impact, for papers by Paul A. Morse
Rankless by CCL
2026